<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773106</url>
  </required_header>
  <id_info>
    <org_study_id>ARGOS-SC01_Follow-up</org_study_id>
    <nct_id>NCT04773106</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Performance of the ARGOS-SC Suprachoroidal Pressure Sensor System in Patients With Glaucoma Underwent Non-penetrating Glaucoma Surgery</brief_title>
  <official_title>Follow-up of the First in Man, Prospective, Open-label, Single Arm, Multicenter Clinical Investigation to Assess the Long-term Safety and Performance of the ARGOS-SC Suprachoroidal Pressure Sensor System in Patients With Glaucoma Underwent Non-penetrating Glaucoma Surgery (Follow-up Month 12 - Month 36)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Implandata Ophthalmic Products GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CRO Dr. med. Kottmann GmbH &amp; Co. KG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Implandata Ophthalmic Products GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-SC&#xD;
      system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a prospective, open-label, multicenter, single-arm clinical&#xD;
      investigation. This study is a follow-up study to the ARGOS-SC01 study (NCT03756662).&#xD;
      Patients who have graduated the ARGOS-SC01 study after 12 month follow-up will be asked to&#xD;
      enroll in this study for an additional 24 month follow-up (month 12-36 post implantation).&#xD;
      This study will be solely observational, as only patients who had implanted the device within&#xD;
      the earlier study will be invited to join this ARGOS-SC01-FU study.&#xD;
&#xD;
      The sensor was always implanted in one eye only which will be the study eye.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Anticipated">February 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Level of Agreement between measurements made using GAT, Pascal DCT and the ARGOS-SC system from V09 (month 12) through V13 (month 36).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of patients experiencing a device-related SAE (SADE)</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Number of patients experiencing a device-related SAE (SADE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of observed adverse events</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Incidence of observed adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Nature of observed adverse events</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Nature of observed adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Severity of observed adverse events</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Severity of observed adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Seriousness of observed adverse events</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Seriousness of observed adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse device events</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Incidence of adverse device events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Nature of adverse device events</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Nature of adverse device events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Severity of adverse device events</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Severity of adverse device events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Seriousness of adverse device events</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Seriousness of adverse device events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Repeatability of the ARGOS-SC measurement (IOP Measurement compared to GAT in mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Incidence of observed device malfunctions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Nature of observed device malfunctions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Seriousness of observed device malfunctions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility</measure>
    <time_frame>Day 360, Day 1080</time_frame>
    <description>User acceptance of the ARGOS-SC system at the investigational site by means of evaluation of physician acceptance questionnaires (by investigators)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility</measure>
    <time_frame>Day 360, Day 1080</time_frame>
    <description>User acceptance of the ARGOS-SC system at home by means of evaluation of patient acceptance questionnaires (patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility</measure>
    <time_frame>Day 360 to Day 1080</time_frame>
    <description>Daily IOP self-measurement profiles (patients)</description>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Glaucoma</condition>
  <condition>Open Angle Glaucoma</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARGOS-SC suprachoroidal pressure sensor</intervention_name>
    <description>Single-arm longterm follow-up ARGOS-SC suprachoroidal pressure Sensor System. The ARGOS-SC suprachoroidal pressure Sensor was already implanted in a previous Study-ARGOS-SC01.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Subjects of the ARGOS-SC01 study with an implanted ARGOS-SC suprachoroidal pressure&#xD;
        sensor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  N/A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Szurman, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Knappschaftsklinikum Saar GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Augenklinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenklinik der LMU München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftsklinikum Saar GmbH, Augenklinik Sulzbach</name>
      <address>
        <city>Sulzbach</city>
        <zip>66280</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swiss Glaucoma Research Foundation, Centre du Glaucome, Clinique Montchoisi</name>
      <address>
        <city>Lausanne</city>
        <zip>1006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-penetrating glaucoma surgery</keyword>
  <keyword>Open angle glaucoma</keyword>
  <keyword>Intraocular pressure measurements</keyword>
  <keyword>Suprachoroidal pressure sensor</keyword>
  <keyword>ARGOS-SC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

